Jennifer L. Eaton

Dr. Jennifer L. Eaton

Women and Infants Hospital, Brown University, Providence, RI, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MSMay-Tal Sauerbrun-Cutler
May-Tal Sauerbrun-Cutler
ARAllegra Rollo
Allegra Rollo
AGAlexis K. Gadson
Alexis K. Gadson
JEJennifer L. Eaton
Jennifer L. Eaton
Fertility preservation (FP) is the use of a specific medical intervention to protect the fertility of individuals whose disease or disease treatment may lead to infertility. These medical interventions include the cryopreservation of oocytes, embryos, ovarian tissue, sperm, and testicular tissue; oocyte and embryo cryopreservation are the most widely used interventions in the United States. Although guidelines recommend FP prior to undergoing gonadotoxic treatments, cost barriers are high. For example, the average cost of an oocyte cryopreservation cycle in the United States exceeds $10,000. High cost and lack of insurance coverage are two of the most cited reasons explaining the low Reproductive Endocrinology and Infertility (REI) referral rates and limited FP utilization. Broadening insurance mandates for FP prior to gonadotoxic treatments could improve utilization and provide cancer survivors with improved quality of life post treatment.

13 February 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AGAlexis K. Gadson
Alexis K. Gadson
MSMay-Tal Sauerbrun-Cutler
May-Tal Sauerbrun-Cutler
JEJennifer L. Eaton
Jennifer L. Eaton
Significant ethnic and racial disparities exist in the utilization and outcomes of assisted reproductive technology (ART) in the United States. The popularity of fertility preservation (FP) procedures, a specific application of ART for those desiring to delay childbearing, has increased; however, many minority populations have seen a less rapid uptake of these services. Minority patients pursuing ART are more likely to have poorer in vitro fertilization (IVF) and pregnancy outcomes. These outcomes are used to predict success after FP and may lessen the appeal of such procedures in these populations. Suboptimal outcomes are further compounded by challenges with receiving referrals to, accessing, and paying for FP services. Resolving these disparities in minority populations will require culturally appropriate education surrounding the benefits of ART and FP, the demonstration of favorable outcomes in ART and FP through continued research engaging minority participants, and continued advocacy for expanded access to care for patients.

10 March 2022 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
JEJennifer L. Eaton
Jennifer L. Eaton

8 September 2021 in F&S Reports
Verified
Journal Article
Open access
BHBenjamin S. Harris
Benjamin S. Harris
KAKelly S. Acharya
Kelly S. Acharya
JWJeremy M. Weber
Jeremy M. Weber
TTTracy Truong
Tracy Truong
JEJennifer L. Eaton
Jennifer L. Eaton
To examine the association between serum antimüllerian hormone (AMH) and live birth among women aged ≥41 years undergoing in vitro fertilization (IVF). Retrospective cohort study using the 2012–2014 Society for Assisted Reproductive Technology Clinic Outcome Reporting System database. Fertility clinics reporting to the Society for Assisted Reproductive Technology. The analysis included 7,819 patients aged ≥41 years who underwent a first fresh, autologous IVF cycle during the study period. Cycles with preimplantation genetic testing were excluded. None. Live birth rate. The empirical distribution of AMH was examined, and extreme values were observed. Therefore, the natural logarithm transformation of AMH (log-AMH) was used in all analyses. Before adjustment for covariates, a one-unit increase in log-AMH was associated with doubling of the odds of live birth up to a log-AMH of −0.34 (equivalently, AMH, 0.71 ng/mL; odds ratio [OR], 2.02; 95% confidence interval [CI], 1.66–2.46). Above an AMH level of 0.71 ng/mL, the odds of live birth increased by only 40% with each unit increase in log-AMH (OR, 1.40; 95% CI, 1.22–1.61). After adjusting for covariates, the odds of live birth increased by 91% with each unit increase in log-AMH up to −0.34 (AMH, 0.71 ng/mL; OR, 1.91; 95% CI, 1.56–2.34). Above an AMH level of 0.71 ng/mL, the odds of live birth increased by only 32% with each unit increase in log-AMH (OR, 1.32; 95% CI, 1.15–1.53). Among women aged ≥41 years undergoing fresh, autologous IVF, the odds of live birth significantly increase with increasing serum AMH level. As the AMH level increases above 0.71 ng/mL, the association maintains statistical significance, but the effect size is diminished.

21 February 2025 in Fertility and Sterility
Verified
Journal Article
Closed access
CVCaroline J. Violette
Caroline J. Violette
JEJennifer L. Eaton
Jennifer L. Eaton

3 December 2024 in Fertility and Sterility
Verified
Journal Article
Closed access
LKLuce A. Kassi
Luce A. Kassi
JEJennifer L. Eaton
Jennifer L. Eaton